SCHEMBL4720904

SCHEMBL4720904

CCCNC1[C]OOc2ccccc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
KMT2A Q03164 4/20 0.35
MAPT P10636 1/20 0.35
MEN1 O00255 3/20 0.34
SIGMAR1 Q99720 1/20 0.34
POLB P06746 1/20 0.33
ESR2 Q92731 1/20 0.33
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 2/20 0.32
SLC6A3 Q01959 2/20 0.32
HTR1A P08908 1/20 0.32
KDM1A O60341 1/20 0.32
HTR2B P41595 1/20 0.32
NPC1 O15118 1/20 0.32
TSHR P16473 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
KCNE1 P15382 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4722883 0.91 BCHE (0.46) BCHEACHEKMT2AMAPTMEN1
SCHEMBL4721239 0.87 KMT2A (0.31) BCHEACHEKMT2AMAPTMEN1
SCHEMBL4719813 0.84 BCHE (0.37) BCHEACHEKMT2AMAPTMEN1
SCHEMBL4720145 0.78 PDPK1 (0.34) KMT2AMEN1
SCHEMBL4721968 0.75 BCHE (0.49) BCHEACHEKMT2AMAPTMEN1
SCHEMBL4720342 0.70 KMT2A (0.33) BCHEACHEKMT2AMAPTMEN1
SCHEMBL4723508 0.69 MEN1 (0.40) KMT2AMEN1SIGMAR1TSHRSMN1; SMN2
SCHEMBL28903352 0.68 BCHE (0.51) BCHEACHEKMT2AMAPTMEN1
SCHEMBL4724712 0.68 MEN1 (0.37) KMT2AMAPTMEN1SIGMAR1SLC6A2
SCHEMBL4723424 0.68 MEN1 (0.39) KMT2AMEN1SIGMAR1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 BCHE 3103/4885ACHE 626/4885KMT2A 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.